M
Martin John Page
Researcher at Research Triangle Park
Publications - 60
Citations - 2981
Martin John Page is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Cancer & Antibody. The author has an hindex of 25, co-authored 59 publications receiving 2863 citations. Previous affiliations of Martin John Page include Johnson & Johnson & University of Liverpool.
Papers
More filters
Journal ArticleDOI
Inhibition of Estrogen Receptor-DNA Binding by the "Pure" Antiestrogen ICI 164,384 Appears to be Mediated by Impaired Receptor Dimerization
TL;DR: It is shown that the "pure" antiestrogen ICI 164,384 inhibits mouse estrogen receptor-DNA binding in vitro, and it is proposed that ICI164,384 reduces DNA binding by interfering with receptor dimerization.
Journal Article
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
David W. Rusnak,Karen Affleck,Stuart Cockerill,Colin Stubberfield,Robert J. Harris,Martin John Page,Kathryn Jane Smith,Stephen Barry Guntrip,Malcolm Clive Carter,Robert Shaw,Amanda Jowett,Jeremy N. Stables,Peter Topley,Edgar R. Wood,Perry Scott Brignola,Sue H. Kadwell,Bryan R. Reep,Robert J. Mullin,Krystal J. Alligood,Barry R. Keith,Renae M. Crosby,Doris M. Murray,W. Blaine Knight,Tona M. Gilmer,Karen Lackey +24 more
TL;DR: Data indicate that quinazoline and pyrido-[3,4-d]-pyrimidine small molecules have potential use as therapy in the broad population of cancer patients overexpressing ErbB-2 and/or EGFR.
Journal ArticleDOI
Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.
Martin John Page,Bob Amess,Raymond R. Townsend,Raj Parekh,Athula Herath,Luc Brusten,Marketa Zvelebil,Robert Stein,Michael D. Waterfield,Sue Davies,Michael J. O'Hare +10 more
TL;DR: This is the most extensive study to date of the protein expression map of the normal human breast and the basis for future studies of purified breast cancer cells.
Journal ArticleDOI
JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Janine Arts,Peter King,Ann Marien,Wim Floren,Ann Beliën,Lut Janssen,Isabelle Noëlle Constance Pilatte,Bruno Roux,Laurence Decrane,Ron Gilissen,Ian Hickson,Veronique Vreys,Eugene Cox,Kees Bol,Willem Talloen,Ilse Goris,Luc Andries,Marc Du Jardin,Michel Janicot,Martin John Page,Kristof Van Emelen,Patrick Angibaud +21 more
TL;DR: The potent antitumor activity as a single agent in preclinical models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising second-generation HDAC inhibitor.
Journal ArticleDOI
Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member.
Edward A. McKenzie,Kerry Louise Tyson,Alasdair Craig Stamps,Paul Smith,Paul Turner,Richard Barry,Margaret L. Hircock,Sonal Patel,Eleanor Barry,Colin Stubberfield,Jon Terrett,Martin John Page +11 more
TL;DR: The cloning of a cDNA encoding a novel human protein, HPA2, with significant homology to heparanase is reported, suggesting that Hpa2 and Hpa1 proteins have distinct biological functions.